Journal
EMBO JOURNAL
Volume 38, Issue 15, Pages -Publisher
WILEY
DOI: 10.15252/embj.2019101654
Keywords
cancer; organoids; preclinical models; tumour heterogeneity; xenografts
Categories
Funding
- Dutch Cancer Society (KWF)/Alpe d'HuZes Bas Mulder Award [10218]
- Oncode Institute
Ask authors/readers for more resources
Patient-derived tumour xenografts and tumour organoids have become important preclinical model systems for cancer research. Both models maintain key features from their parental tumours, such as genetic and phenotypic heterogeneity, which allows them to be used for a wide spectrum of applications. In contrast to patient-derived xenografts, organoids can be established and expanded with high efficiency from primary patient material. On the other hand, xenografts retain tumour-stroma interactions, which are known to contribute to tumorigenesis. In this review, we discuss recent advances in patient-derived tumour xenograft and tumour organoid model systems and compare their promises and challenges as preclinical models in cancer research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available